Palisade Bio (PALI) Oppenheimer has initiated coverage on Palisade Bio with an Outperform rating and an $8 price target. Current Price: $2.03 (+7%) Sector: Biotechnology Key Highlights: • Oppenheimer starts coverage with Outperform rating • $8 price target implies significant upside • Highlights promising early clinical data for oral IBD candidate PALI-2108 • First Phase 2 data expected in 2027 Why It Matters: The analyst believes PALI-2108’s locally acting design could offer a differentiated profile in the IBD space with reduced systemic side effects. This initiation reflects growing institutional interest ahead of key clinical readouts. Ticker: #PALI Focus: IBD Treatment, Clinical Pipeline https://www.thinksabio.com/reports/isr/PALI